Myriad Genetics Inc. announced an international team of cancer researchers has found EndoPredict test accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy. Findings from the study were published in the journal, Breast Cancer Research and Treatment.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
